Monitor the company's progress on the NYSE cure plan (18 months from July 2026) and the restructuring plan execution. The massive overhang of registered shares for resale by major holders could pressure the stock. Watch for any further PIPE or capital raises given negative equity and limited cash runway.
Executive Summary
Wallbox N.V. filed Amendment No. 1 to its F-1 registration statement to register up to 14,045,412 Class A shares for resale by selling securityholders and a small settlement share issuance. The filing covers 10,369,681 PIPE shares from private placements in 2025 and 2026, up to 3,531,696 warrant shares, and 144,035 settlement shares at $2.89 per share. The company is in the midst of a court-approved restructuring plan that refinances approximately €169.6 million of debt, has negative equity of -$59.6 million as of June 30, 2026, and is on an 18-month NYSE cure plan to regain compliance with continued listing standards.
Key Facts
- Registration covers up to 14,045,412 Class A shares: 10,369,681 PIPE shares, up to 3,531,696 warrant shares, and 144,035 settlement shares at $2.89 each.
- Company has negative equity of -$59.6 million as of June 30, 2026, with an accumulated deficit of -$722.5 million.
- Non-current debt of $140.1 million; restructuring plan approved by Commercial Court of Barcelona in May 2026 refinances approximately €169.6 million of financial indebtedness.
- NYSE accepted a compliance plan on July 6, 2026, with an 18-month cure period requiring stockholders' equity of at least $50 million or average market cap of $50 million.
- Cash and cash equivalents of $19.9 million as of June 30, 2026; company expects up to ~$23 million from warrant exercises for general corporate purposes.
- Selling securityholders include Generac Power Systems (11.42% pre-offering), IFEM (12.71%), Focus on Next Frontier (10.38%), and others; several selling holders would reduce stakes to near zero after the offering.
Financial Impact
Up to 14.0M shares registered for resale, representing ~60% of the 23.5M shares outstanding; potential warrant exercise proceeds of ~$23M; company has negative equity of -$59.6M and $140.1M in non-current debt.
Risk Factors
- NYSE delisting risk if cure plan conditions not met within 18 months
- Massive dilution from up to 14M shares registered for resale by selling securityholders
- Negative equity of -$59.6M and accumulated deficit of -$722.5M indicate severe financial distress
- Restructuring plan may not succeed; company has history of operating losses
- Warrant exercises could add further dilution if cash exercise occurs
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| F-1/A Filing (Primary) | 0001193125-26-428990 |
| Document: d100826dex51.htm | 0001193125-26-428990 |
| Document: d100826dexfilingfees.htm | 0001193125-26-428990 |
| Document: d100826dex231.htm | 0001193125-26-428990 |
| Document: 0001193125-26-428990-index-headers.html | 0001193125-26-428990 |
| Document: 0001193125-26-428990-index.html | 0001193125-26-428990 |
| Document: 0001193125-26-428990.txt | 0001193125-26-428990 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | F-1/A | $2.65 $2.67 | ▼ −0.75% | ▼ −0.04% | $2.67 (−0.75%) |
Jul 2, 2026 16w ago | Insider Cluster | $4.16 $5.62 | ▲ +35.10% | ▲ +34.22% | $2.67 (−35.82%) |
Jul 2, 2026 16w ago | Insider Cluster | $4.16 $5.62 | ▲ +35.10% | ▲ +34.22% | $2.67 (−35.82%) |
Jul 2, 2026 16w ago | 6-K | $4.16 $5.62 | ▲ +35.10% | ▲ +34.22% | $2.67 (−35.82%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers